Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
In the seminal UK Prospective Diabetes Study, a 1% reduction in HbA1c was associated with important risk reductions in any diabetes-related end point, diabetes-related deaths, myocardial infarction, and microvascular complications. Here, we examine the drug cost of canagliflozin 100 and 300mg, dapagliflozin 10mg, and empagliflozin 10 and 25mg per a 1% reduction in HbA1c.
Insulin therapy is associated with weight gain and hypoglycemia, and patients and physicians generally prefer to postpone insulin use. SGLT2 inhibitors provide substantial and sustained HbA1c lowering, weight loss, and blood pressure control in patients with T2DM, and are generally well tolerated. Indirect comparisons of clinical trial data suggest that these agents have differential efficacy.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
